Effects of the combination of neprilisin and angiotensin receptor inhibition (Sacubitril/Valsartan, i.e. ARNI) on cardiopulmonary exercise test
Latest Information Update: 07 Oct 2019
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
Most Recent Events
- 07 Oct 2019 New trial record
- 02 Oct 2019 Results published in the Acta Cardiologica